Currency In USD
| Previous Close | 0.41 |
| Open | 0.41 |
| Day High | 0.44 |
| Day Low | 0.39 |
| 52-Week High | 19.11 |
| 52-Week Low | 0.39 |
| Volume | 31.42M |
| Average Volume | 8.07M |
| Market Cap | 36.05M |
| PE | -0.11 |
| EPS | -3.74 |
| Moving Average 50 Days | 4.43 |
| Moving Average 200 Days | 11.55 |
| Change | 0.02 |
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
GlobeNewswire Inc.
Mar 02, 2026 12:00 PM GMT
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc.
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will
EyePoint Appoints Michael Campbell as Chief Commercial Officer
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucen